http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-1173212-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fcc98b42717527a355228452491869d2
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-41
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-12
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-41
filingDate 1967-05-08-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationDate 1969-12-03-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber GB-1173212-A
titleOfInvention Hydantoins and processes for the preparation thereof
abstract 1,173,212. Nitrofuran derivatives. ETABS. CLIN-BYLA. 8 May, 1967 [9 May, 1966], No. 21364/67. Heading C2C. Novel nitrofuran derivatives of Formula I in which Alk is alkylene or alkenylene and R is (a) a hydroxy or cyano group or an alkoxy, acyloxy, carbalkoxy or alkoxycarbonylamino group having 1 to 3 carbon atoms (b) a group of formula -O.CO.R1.COOH in which R<SP>1</SP> is a divalent aliphatic or aromatic group present in a dicarboxylic acid which forms an anhydride, or (c) an open chain or cyclic tertiary amino group which may contain an additional hetero atom in the ring, and salts of compounds under (b) with alkali metals, ammonia and organic bases and salts of compounds under (c) with acids, are prepared (i) (for compounds I in which R = R<SP>11</SP> = a group falling under (a) or (c) except for cyano), by reacting a compound of Formula II with #-(5-nitro-2-furyl) acrolein, or (ii) (for compounds I in which R = R<SP>111</SP> = a groug falling under (a) or (c) except for hydroxy or cyano) by reacting a 3-alkali metal derivative of 1-[#-(5-nitro-2-furyl) allylidene amino] -hydantoin with a halide of formula: XAlkR<SP>111</SP> in which X is a halogen atom, or (iii) (for the compound I in which R is hydroxy and Alk is methylene), by methylolating 1-[#-(5-nitro-2- furyl)-allylideneamino] hydantoin, or (iv) (for compounds I in which R is C 1-3 acyloxy or a group falling under (b)), by treating a 1-[#-(5- nitro-2-furyl)-allylideneamino]-3-hydroxyalkylhydantoin with an acyl halide or with the anhydride of a monocarboxylic acid or of a dicarboxylic acid which forms an anhydride, or (v) (for the compound I in which R is cyano and Alk is ethylene), by treating 1.[#-(5-nitro-2- furyl)-allylidene amino] hydantoin with acrylonitrile in the presence of a mutal solvent therefor or (vi) (for compounds I in which R is a secondary amino group and Alk is methylene), by reacting 1-[#-(5-nitro-2-furyl) allylideneamino] - 3 - hydroxymethylhydantoin with a secondary amine, or (vii) by forming a salt of an appropriate compound I by a conventional method. 1 - [# - (5 - Nitro - 2 - furyl) - allylideneamino] hydantoin is prepared by 2-aminohydantoin hydrochloride with #-(5-nitro-2- furyl) acrolein or its diacetate. 1 - Benzylideneamino - 3 - carbethoxy - hydantoin is prepared by reacting benzaldehyde semicarbazone with ethyl chloroacetate. Pharmaceutical compositions having antibacterial activity, for oral, parenteral or topical administration, comprise a compound I, or a salt thereof, together with carrier.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5332832-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-03095431-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-101792433-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9841520-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2015181741-A1
priorityDate 1966-05-09-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID432473755
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID426120671
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID7855
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID7751
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419557048
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID454973655
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458397310
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419549379
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID222
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5369387
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419559542
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458396226
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419508577
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID10006
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID7847
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID154367775
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419550829
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID313
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419527198
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419559464
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458393818
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6325
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID456171974
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5353356
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID409298605

Total number of triples: 42.